A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...

Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...

Novartis NVS announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the ...

The FDA has granted breakthrough therapy designation to Novartis’ ianalumab for Sjögren’s disease, according to a press release from the manufacturer.In its statement, Novartis said it plans to submit ...

Ianalumab receives FDA Breakthrough Therapy status for Sjögren disease following positive findings from two phase 3 clinical trial programs.

US FDA grants Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease: Basel Monday, January 19, 2026, 12:00 Hrs [IST] Novartis announced that the US Fo ...

Hepatocellular carcinoma (HCC), characterized by high aggressiveness and recurrence, poses a significant global health challenge. The interplay between the tumour microenvironment and exogenous ...

A team from the Würzburg Institute of Experimental Biomedicine I and the Rudolf Virchow Center (RVZ) has fundamentally changed our understanding of ...

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently ...

Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette ...